Guizhi-Shaoyao-Zhimu decoction attenuates rheumatoid arthritis partially by reversing inflammation-immune system imbalance

Journal of Translational Medicine

Volumn 14, Issue 1, 2016, Pages

  Guo, Qiuyan ^a   Mao, Xia ^a   Zhang, Yanqiong ^a   Meng, Shuqin ^b   Xi, Yue ^b   Ding, Yi ^b   Zhang, Xiaocun ^c   Dai, Yuntao ^a   Liu, Xia ^c   Wang, Chao ^a   Li, Yuting ^a   Lin, Na ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b PEKING UNIVERSITY   (China)

^c WUHAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Experimental validation; Guizhi Shaoyao Zhimu decoction; Network pharmacology; Rheumatoid arthritis; TCM herbal formula

Indexed keywords

ANTIINFLAMMATORY AGENT; B LYMPHOCYTE RECEPTOR; GUIZHI SHAOYAO ZHIMU DECOCTION; HEAT SHOCK PROTEIN 90 ALPHA; HISTONE DEACETYLASE 1; I KAPPA B; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHOTREXATE; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; GUIZHI-SHAOYAO-ZHIMU DECOCTION; HERBACEOUS AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG MECHANISM; DRUG TARGETING; IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR DYNAMICS; NONHUMAN; OSTEOCLAST; RAT; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; VALIDATION STUDY; ANIMAL; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; IMMUNE SYSTEM; INFLAMMATION; JOINT; LEWIS RAT; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SYNOVITIS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; IMMUNE SYSTEM; INFLAMMATION; JOINTS; MALE; RATS, INBRED LEW; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SYNOVITIS;

EID: 84975744132     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-016-0921-x     Document Type: Article

References (54)

1. Gravallese E. Bone destruction in arthritis. Ann Rheum Dis. 2002;61(2):84-6.
2. Wang D, Li Y, Liu Y, Shi G. The use of biologic therapies in the treatment of rheumatoid arthritis. Curr Pharm Biotechnol. 2014;15:542-8.
3. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11:229.
4. Papadopoulos I, Demetzos C, Markantoni-Kyroudi S, Souliotis K. The safety of biological medicines for rheumatoid arthritis. Adv Exp Med Biol. 2015;822:209-10.
5. Urushibara M, Takayanagi H, Koga T, Kim S, Isobe M, Morishita Y, Nakagawa T, Löeffler M, Kodama T, Kurosawa H, Taniguchi T. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum. 2004;50:794-804.
6. Andersson AK, Li C, Brennan FM. Recent developments in the immunobiology of rheumatoid arthritis. Arthritis Res Ther. 2008;10:204.
7. Lee WY, Chen HY, Chen KC, Chen CY. Treatment of rheumatoid arthritis with traditional chinese medicine. Biomed Res Int. 2014;2014:528018.
8. Liu J, Liu RL. The potential role of Chinese medicine in ameliorating extra-articular manifestations of rheumatoid arthritis. Chin J Integr Med. 2011;17:735-7.
9. Chen J, Zhao H, Shen X. Effect of tongbiling on synoviocyte function in adjuvant arthritis rats. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1999;19(3):167-9.
10. Li DH, Hu ZG, Gao M. A clinical observation of Guizhi-Shaoyao-Zhimu decoction in the treatment of 143 patients with rheumatoid arthritis. Shanxi J Tradit Chin Med. 1997;13(3):16.
11. Liu XY, Yu P. A clinical observation of Guizhi-Shaoyao-Zhimu decoction in the treatment of 83 patients with rheumatoid arthritis. J Guiyang Tradit Chin Med. 2003;25(4):23-4.
12. An XX. A clinical observation of Guizhi-Shaoyao-Zhimu decoction in the treatment of 48 patients with rheumatoid arthritis. Gansu Tradit Chin Med. 2001;14(1):31-2.
13. Xie B, Tian XF. A clinical observation of Guizhi-Shaoyao-Zhimu decoction in the treatment of 60 patients with rheumatoid arthritis. J Hunan Tradit Chin Med. 2003;23(5):49-51.
14. Shen X, Li C, Zhao H, Li S, Chen J, Kobayashi Y, Shen W. Inhibitory effects of a traditional Chinese herbal formula TBL-II on type II collagen-induced arthritis in mice. J Ethnopharmacol. 2011;134:399-405.
15. Yu T, Qing MS, Xiao W. Study of the regulatory effect of Guizhi-Shaoyao-Zhimu decoction on RA synovial cell apoptosis. Cont Med. 2010;16:18-20.
16. Zhu WW, Chen LP, Yao J, Zhang JS. Study on effect of Guizhi-Shaoyao-Zhimu decoction combined with disease-modifying drugs to treat senile active rheumatoid arthritis. Liaoning J Tradit Chin Med. 2013;40:132-5.
17. Wermuth CG. Multi-targeted drugs: the end of the "one-target-one disease" philosophy? Drug Discov Today. 2004;9:826-7.
18. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4:682-90.
19. Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med. 2013;11:110-20.
20. Li S, Fan TP, Jia W, Lu A, Zhang W. Network pharmacology in traditional chinese medicine. Evid Based Complement Alternat Med. 2014;2014:138460.
21. Chen CY. TCM DatabaseatTaiwan: the world's largest traditional Chinese medicine database for drug screening in silico. PLoS One. 2011;6:e15939.
22. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008;36:D901-6.
23. Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA. Online Mendelian inheritance in man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res. 2005;33:D514-7.
24. Becker KG, Barnes KC, Bright TJ, Wang SA. The genetic association database. Nat Genet. 2004;36:431-2.
25. Wixon J, Kell D. The Kyoto encyclopedia of genes and genomes-KEGG. Yeast. 2000;17:48-55.
26. Chen JY, Mamidipalli S, Huan T. HAPPI: an online database of comprehensive human annotated and predicted protein interactions. BMC Genom. 2009;10(Suppl 1):S16.
27. Matthews L, Gopinath G, Gillespie M, Caudy M, Croft D, de Bono B, Garapati P, Hemish J, Hermjakob H, Jassal B, Kanapin A, Lewis S, Mahajan S, May B, Schmidt E, Vastrik I, Wu G, Birney E, Stein L, D'Eustachio P. Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res. 2009;37:D619-22.
28. Brown KR, Jurisica I. Online predicted human interaction database. Bioinformatics. 2005;21:2076-82.
29. Aranda B, Achuthan P, Alam-Faruque Y, Armean I, Bridge A, Derow C, Feuermann M, Ghanbarian AT, Kerrien S, Khadake J, Kerssemakers J, Leroy C, Menden M, Michaut M, Montecchi-Palazzi L, Neuhauser SN, Orchard S, Perreau V, Roechert B, van Eijk K, Hermjakob H. The IntAct molecular interaction database in 2010. Nucleic Acids Res. 2010;38:D525-31.
30. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, Telikicherla D, Raju R, Shafreen B, Venugopal A, Balakrishnan L, Marimuthu A, Banerjee S, Somanathan DS, Sebastian A, Rani S, Ray S, Harrys Kishore CJ, Kanth S, Ahmed M, Kashyap MK, Mohmood R, Ramachandra YL, Krishna V, Rahiman BA, Mohan S, Ranganathan P, Ramabadran S, Chaerkady R, Pandey A. Human protein reference database-2009 update. Nucleic Acids Res. 2009;37:D767-72.
31. Ceol A, Chatr Aryamontri A, Licata L, Peluso D, Briganti L, Perfetto L, Castagnoli L, Cesareni G. MINT, the molecular interaction database: 2009 update. Nucleic Acids Res. 2010;38:D532-9.
32. Lehne B, Schlitt T. Protein-protein interaction databases: keeping up with growing interactomes. Hum. Genomics. 2009;3:291-7.
33. Beuming T, Skrabanek L, Niv MY, Mukherjee P, Weinstein H. PDZBase: a protein-protein interaction database for PDZ-domains. Bioinformatics. 2005;21:827-8.
34. Guo Q, Zhong M, Xu H, Mao X, Zhang Y, Lin N. A systems biology perspective on the molecular mechanisms underlying the therapeutic effects of Buyang Huanwu decoction on ischemic stroke. Rejuvenation Res. 2015;18:313-25.
35. Zhang Y, Guo X, Wang D, Li R, Li X, Xu Y, Liu Z, Song Z, Lin Y, Li Z, Lin N. A systems biology-based investigation into the therapeutic effects of Gansui Banxia Tang on reversing the imbalanced network of hepatocellular carcinoma. Sci Rep. 2014;4:4154.
36. Zhang Y, Bai M, Zhang B, Liu C, Guo Q, Sun Y, Wang D, Wang C, Jiang Y, Lin N, Li S. Uncovering pharmacological mechanisms of Wu-tou decoction acting on rheumatoid arthritis through systems approaches: drug-target prediction, network analysis and experimental validation. Sci Rep. 2015;5:9463.
37. Vieira EM, Goodman S, Tanaka PP. Anesthesia and rheumatoid arthritis. Rev Bras Anestesiol. 2011;61:367-75.
38. Yao Y, Zhang X, Wang Z, Zheng C, Li P, Huang C, Tao W, Xiao W, Wang Y, Huang L, Yang L. Deciphering the combination principles of traditional Chinese medicine from a systems pharmacology perspective based on Ma-huang decoction. J Ethnopharmacol. 2013;150:619-38.
39. Zhou LM, Tao J. The analysis of the composing principle of Guizhi-Shaoyao-Zhimu decoction. J Changchun Univ Tradit Chin Med. 2012;28:1100 (in Chinese).
40. Li S, Zhang B, Jiang D, Wei Y, Zhang N. Herb network construction and co-module analysis for uncovering the combination rule of traditional Chinese herbal formulae. BMC Bioinform. 2010;11(Suppl 11):S6.
41. Sun LX, Wang Y. Research and advance in rheumatic arthristis treated with Guizhi Shao yaoZhimu soup. Forum Tradit Chin Med. 2007;22:23-4 (in Chinese).
42. Zheng FH, Wei P, Huo HL, Xing XF, Chen FL, Tan XM, Luo JB. Neuroprotective effect of gui zhi (ramulus cinnamomi) on ma huang- (herb ephedra-) induced toxicity in rats treated with a ma huang-gui zhi herb pair. Evid Based Complement Alternat Med. 2015;2015:913461.
43. Zhou LM, Tao J. The analysis of the composing principle of Guizhi-Shaoyao-Zhimu decoction. J Changchun Univ Tradit Chin Med. 2012;28:1100 (in Chinese).
44. Li GS. The prescription analysis and clinical application of Guizhi-Shaoyao-Zhimu decoction and wutou decoction. J Tradit Chin Med Lit. 2008;26:23-4 (in Chinese).
45. Li S, Zhang ZQ, Wu LJ, Zhang XG, Li YD, Wang YY. Understanding ZHENG in traditional Chinese medicine in the context of neuro-endocrine-immune network. IET Syst Biol. 2007;1:51-60.
46. Put S, Westhovens R, Lahoutte T, Matthys P. Molecular imaging of rheumatoid arthritis: emerging markers, tools and techniques. Arthritis Res Ther. 2014;16:208.
47. Narayanan T, Gersten M, Subramaniam S, Grama A. Modularity detection in protein-protein interaction networks. BMC Res Notes. 2011;4:569.
48. Ahmed AS, Li J, Ahmed M, Hua L, Yakovleva T, Ossipov MH, Bakalkin G, Stark A. Attenuation of pain and inflammation in adjuvant-induced arthritis by the proteasome inhibitor. Arthritis Rheum. 2010;62:2160-9.
49. Meyer P, Burkhardt H, Palombo-Kinne E, Gründer W, Bräuer R, Stiller KJ, Kalden JR, Becker W, Kinne RW. 123I-antileukoproteinase scintigraphy reveals microscopic cartilage alterations in the contralateral knee joint of rats with "monarticular" antigen-induced arthritis. Arthritis Rheum. 2000;43:298-310.
50. Hammaker D, Boyle DL, Firestein GS. Synoviocyte innate immune responses: TANK-binding kinase-1 as a potential therapeutic target in rheumatoid arthritis. Rheumatology (Oxford). 2012;51:610-8.
51. Kawabata T, Nishida K, Takasugi K, Ogawa H, Sada K, Kadota Y, Inagaki J, Hirohata S, Ninomiya Y, Makino H. Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis. Arthritis Res Ther. 2010;12:R133.
52. Ha MK, Song YH, Jeong SJ, Lee HJ, Jung JH, Kim B, Song HS, Huh JE, Kim SH. Emodin inhibits proinflammatory responses and inactivates histone deacetylase 1 in hypoxic rheumatoid synoviocytes. Biol Pharm Bull. 2011;34:1432-7.
53. Rice JW, Veal JM, Fadden RP, Barabasz AF, Partridge JM, Barta TE, Dubois LG, Huang KH, Mabbett SR, Silinski MA, Steed PM, Hall SE. Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum. 2008;58:3765-75.
54. Campbell J, Ciesielski CJ, Hunt AE, Horwood NJ, Beech JT, Hayes LA, Denys A, Feldmann M, Brennan FM, Foxwell BM. A novel mechanism for TNF-alpha regulation by p38 MAPK: involvement of NF-kappa B with implications for therapy in rheumatoid arthritis. J Immunol. 2004;173:6928-37.